Bernhard Nieswandt
“The role of platelets in acute stroke“
Stroke is the second leading cause of death worldwide with limited treatment options. Rapid restoration of blood flow by thrombolysis or thrombectomy is the mainstay of acute stroke treatment, but recanalisation of cerebral vessels may trigger ischemia/reperfusion injury and thus infarct growth “despite reperfusion”. Increasing experimental evidence now suggests that this cerebral I/R injury is a complex pathology since it involves concerted detrimental actions of platelets and T-cells, referred to as “thrombo-inflammation” which will be discussed in this webinar.
Martine Jandrot-Perrus
"GPVI as a novel target in thrombosis"
Dr Jandrot-Perrus will review the characteristics of platelet Glycoprotein VI (GPVI) and why GPVI is currently considered to meet the challenge of developing a safe and effective antiplatelet drug.
- Basic and clinical scientists in the fields of thrombosis and haemostasis, inflammation, stroke and animal models of disease
- Students, researchers and clinicians interested in translational research
At the conclusion of this activity, I will be able to:
- Detailed understanding of the tMCAO stroke model and the concept of “thrombo-inflammation” as the major pathomechanism underlying cerebral infarct growth in the setting of acute “experimental” stroke
- Update knowledge on a specific platelet activation pathway differentially involved in thrombosis and physiological haemostasis
Bernhard Nieswandt
“The role of platelets in acute stroke“
Stroke is the second leading cause of death worldwide with limited treatment options. Rapid restoration of blood flow by thrombolysis or thrombectomy is the mainstay of acute stroke treatment, but recanalisation of cerebral vessels may trigger ischemia/reperfusion injury and thus infarct growth “despite reperfusion”. Increasing experimental evidence now suggests that this cerebral I/R injury is a complex pathology since it involves concerted detrimental actions of platelets and T-cells, referred to as “thrombo-inflammation” which will be discussed in this webinar.
Martine Jandrot-Perrus
"GPVI as a novel target in thrombosis"
Dr Jandrot-Perrus will review the characteristics of platelet Glycoprotein VI (GPVI) and why GPVI is currently considered to meet the challenge of developing a safe and effective antiplatelet drug.
Name | Company | Role |
Geoffrey Barnes, MD | Portola | Consulting |
Blue Cross Blue Shield of Michigan | Research | |
BMS/Pfizer | Research | |
Chris Ward, PhD | Bayer | Speaker |
Boehringer-Ingelheim | Speaker, Advisory Board | |
BMS/Pfizer | Speaker, Advisory Board | |
Martine Jandrot-Perrus | Acticor Biotech | Advisory Scientist |
In accordance with the ACCME® Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved.
Contact
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.